




Filana Therapeutics INC

Rank 73 of 308

The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Filana Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 341%, being 96% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	19,070
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	665
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	107
Property and Equipment	232
Research and Development	9,176
Selling, General and Administrative Expense	5,781

Output Variable	Value in 1000 USD
Assets	19,302
Liabilities	665
Expenses	14,957
Revenues	107
Stockholders Equity	18,637
Net Income	-14,850
Comprehensive Net Income	-14,850
BaseVar	17,516
ECR before LimitedLiability	258%
Economic Capital Ratio	341%